Breast Cancer Surgery 10-Year Survival Prediction by Machine Learning: A Large Prospective Cohort Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Design of Study and Participants
2.2. Five Forecasting Models
2.3. Potential Predictors
2.4. Statistical Analysis
3. Results
3.1. Study Characteristics
3.2. Comparison of Forecasting Models
3.3. Significant Predictors in the DNN Model
3.4. Sensitivity Analysis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wang, F.; Shu, X.; Meszoely, I.; Pal, T.; Mayer, I.A.; Yu, Z.; Zheng, W.; Bailey, C.E.; Shu, X.O. Overall Mortality After Diagnosis of Breast Cancer in Men vs. Women. JAMA Oncol. 2019, 5, 1589–1596. [Google Scholar] [CrossRef] [PubMed]
- Chu, Q.D.; Hsieh, M.C.; Lyons, J.M.; Wu, X.C. 10-Year Survival after Breast-Conserving Surgery Compared with Mastectomy in Louisiana Women with Early-Stage Breast Cancer: A Population-Based Study. J. Am. Coll. Surg. 2021, 232, 607–621. [Google Scholar] [CrossRef]
- Cotzomi-Ortega, I.; Rosas-Cruz, A.; Ramírez-Ramírez, D.; Reyes-Leyva, J.; Rodriguez-Sosa, M.; Aguilar-Alonso, P.; Maycotte, P. Autophagy Inhibition Induces the Secretion of Macrophage Migration Inhibitory Factor (MIF) with Autocrine and Paracrine Effects on the Promotion of Malignancy in Breast Cancer. Biology 2020, 9, 20. [Google Scholar] [CrossRef] [Green Version]
- Moncada-Torres, A.; van Maaren, M.C.; Hendriks, M.P.; Siesling, S.; Geleijnse, G. Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival. Sci. Rep. 2021, 11, 6968. [Google Scholar] [CrossRef] [PubMed]
- Kuruc, F.; Binder, H.; Hess, M. Stratified neural networks in a time-to-event setting. Brief. Bioinform. 2021. online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Chen, N.; Guo, J.; Xu, X.; Liu, L.; Yi, Z. SurvNet: A Novel Deep Neural Network for Lung Cancer Survival Analysis with Missing Values. Front. Oncol. 2021, 10, 588990. [Google Scholar] [CrossRef] [PubMed]
- Bhambhvani, H.P.; Zamora, A.; Velaer, K.; Greenberg, D.R.; Sheth, K.R. Deep learning enabled prediction of 5-year survival in pediatric genitourinary rhabdomyosarcoma. Surg. Oncol. 2021, 36, 23–27. [Google Scholar] [CrossRef]
- Hou, C.; Zhong, X.; He, P.; Xu, B.; Diao, S.; Yi, F.; Zheng, H.; Li, J. Predicting Breast Cancer in Chinese Women Using Machine Learning Techniques: Algorithm Development. JMIR Med. Inform. 2020, 8, e17364. [Google Scholar] [CrossRef] [PubMed]
- Munir, K.; Elahi, H.; Ayub, A.; Frezza, F.; Rizzi, A. Cancer Diagnosis Using Deep Learning: A Bibliographic Review. Cancers 2019, 11, 1235. [Google Scholar] [CrossRef] [Green Version]
- Wu, N.; Jastrzębski, S.; Park, J.; Moy, L.; Cho, K.; Geras, K.J. Improving the Ability of Deep Neural Networks to Use Information from Multiple Views in Breast Cancer Screening. Proc. Mach. Learn. Res. 2020, 121, 827–842. [Google Scholar]
- Srivastava, N.; Hinton, G.; Krizhevsky, A.; Sutskever, I.; Salakhutdinov, R. Dropout: A simple way to prevent neural networks from overfitting. J. Mach. Learn. Res. 2014, 15, 1929–1958. [Google Scholar]
- Altman, N.S. An introduction to kernel and nearest-neighbor nonparametric regression. Am. Stat. 1992, 46, 175–185. [Google Scholar]
- Cortes, C.; Vapnik, V. Support-vector networks. Mach. Learn. 1995, 20, 273–297. [Google Scholar] [CrossRef]
- Domingos, P.; Pazzani, M. On the optimality of the simple Bayesian classifier under zero-one loss. Mach. Learn. 1997, 29, 103–137. [Google Scholar] [CrossRef]
- Bender, R.; Augustin, T.; Blettner, M. Generating survival times to simulate Cox proportional hazards models. Stat. Med. 2006, 24, 1713–1723. [Google Scholar] [CrossRef] [Green Version]
- Tseng, H.M.; Lu, J.F.; Gandek, B. Cultural Issues in Using the SF-36 Health Survey in Asia: Results from Taiwan. Health Qual. Life Outcomes 2003, 1, 72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gandek, B.; Ware, J.E. Methods for validating and norming translations of health status questionnaires: The IQOLA Project approach. J. Clin. Epidemiol. 1998, 51, 953–959. [Google Scholar] [CrossRef]
- Melton, L.J. Selection bias in the referral of patients and the natural history of surgical conditions. Mayo Clin. Proc. 1985, 60, 880–889. [Google Scholar] [CrossRef] [Green Version]
- Ryu, H.S.; Jin, M.S.; Park, J.H.; Lee, S.; Cho, J.; Oh, S.; Kwak, T.Y.; Woo, J.I.; Mun, Y.; Kim, S.W.; et al. Automated Gleason Scoring and Tumor Quantification in Prostate Core Needle Biopsy Images Using Deep Neural Networks and Its Comparison with Pathologist-Based Assessment. Cancers 2019, 11, 1860. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bejnordi, B.E.; Veta, M.; van Diest, P.J.; van Ginneken, B.; Karssemeijer, N.; Litjens, G.; van der Laak, J.A.W.M.; Consortium, C.; Hermsen, M.; Manson, Q.F.; et al. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women with Breast Cancer. JAMA 2017, 318, 2199–2210. [Google Scholar] [CrossRef]
- Tat Dat, T.; Frédéric, P.; Hang, N.T.T.; Jules, M.; Duc Thang, N.; Piffault, C.; Willy, R.; Susely, F.; Lê, H.V.; Tuschmann, W.; et al. Epidemic Dynamics via Wavelet Theory and Machine Learning with Applications to COVID-19. Biology 2020, 9, 477. [Google Scholar] [CrossRef]
- Hall, P.S.; Swinson, D.; Cairns, D.A.; Waters, J.S.; Petty, R.; Allmark, C.; Ruddock, S.; Falk, S.; Wadsley, J.; Roy, R.; et al. Efficacy of Reduced-Intensity Chemotherapy with Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients with Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021, 7, 869–877. [Google Scholar] [CrossRef]
- Karvonen-Gutierrez, C.A.; Ronis, D.L.; Fowler, K.E.; Terrell, J.E.; Gruber, S.B.; Duffy, S.A. Quality of life scores predict survival among patients with head and neck cancer. J. Clin. Oncol. 2008, 26, 2754–2760. [Google Scholar] [CrossRef]
- Chiu, C.C.; Lee, K.T.; Wang, J.J.; Sun, D.P.; Lee, H.H.; Huang, C.C.; Shi, H.Y. Preoperative Health-Related Quality of Life Predicts Minimal Clinically Important Difference and Survival after Surgical Resection of Hepatocellular Carcinoma. J. Clin. Med. 2019, 8, 576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quinten, C.; Coens, C.; Mauer, M.; Comte, S.; Sprangers, M.A.G.; Cleeland, C.; Osoba, D.; Bjordal, K.; Bottomley, A.; EORTC Clinical Groups. EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009, 10, 865–871. [Google Scholar] [CrossRef]
- Sopik, V.; Nofech-Mozes, S.; Sun, P.; Narod, S.A. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res. Treat. 2016, 155, 175–185. [Google Scholar] [CrossRef] [PubMed]
- Pucher, P.H.; Aggarwal, R.; Qurashi, M.; Darzi, A. Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival. Br. J. Surg. 2014, 101, 1499–1508. [Google Scholar] [CrossRef]
- Li, Z.L.; Yan, W.T.; Zhang, J.; Zhao, Y.J.; Lau, W.Y.; Mao, X.H.; Zeng, Y.Y.; Zhou, Y.H.; Gu, W.M.; Wang, H.; et al. Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: A Multicenter Study. J. Gastrointest. Surg. 2019, 23, 288–296. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.F.; Chong, C.N.; Fong, K.W.; Fung, A.K.Y.; Lok, H.T.; Cheung, Y.S.; Wong, J.; Lai, P.B.S. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: Experience from a single center. Hepatobiliary Surg. Nutr. 2018, 7, 320–330. [Google Scholar] [CrossRef]
- Chou, W.C.; Liu, K.H.; Lu, C.H.; Hung, Y.S.; Chen, M.F.; Cheng, Y.F.; Wang, C.H.; Lin, Y.C.; Yeh, T.S. To Operate or Not: Prediction of 3-Month Postoperative Mortality in Geriatric Cancer Patients. J. Cancer 2016, 7, 14–21. [Google Scholar] [CrossRef] [Green Version]
- Kurian, A.W.; Lichtensztajn, D.Y.; Keegan, T.H.M.; Nelson, D.O.; Clarke, C.A.; Gomez, S.L. Use of and Mortality After Bilateral Mastectomy Compared with Other Surgical Treatments for Breast Cancer in California, 1998–2011. JAMA 2014, 312, 902–914. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quinten, C.; Martinelli, F.; Coens, C.; Sprangers, M.A.G.; Ringash, J.; Gotay, C.; Bjordal, K.; Greimel, E.; Reeve, B.B.; Maringwa, J.; et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer 2014, 120, 302–311. [Google Scholar] [CrossRef] [PubMed]
- Heijl, M.V.; Sprangers, M.A.G.; de Boer, A.G.E.M.; Lagarde, S.M.; Reitsma, H.B.; Busch, O.R.C.; Tilanus, H.W.; van Lanschot, J.J.B.; van Berge Henegouwen, M.I. Preoperative and Early Postoperative Quality of Life Predict Survival in Potentially Curable Patients with Esophageal Cancer. Ann. Surg. Oncol. 2010, 17, 23–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, L.; Lin, J.; Chen, L.Z.; Chen, Y.; Wang, X.J.; Guo, Z.Q.; Yu, J.M. Perineural Invasion and Postoperative Complications are Independent Predictors of Early Recurrence and Survival Following Curative Resection of Gastric Cancer. Cancer Manag. Res. 2020, 12, 7601–7610. [Google Scholar] [CrossRef]
- Huh, J.W.; Kim, C.H.; Lim, S.W.; Kim, H.R.; Kim, Y.J. Early recurrence in patients undergoing curative surgery for colorectal cancer: Is it a predictor for poor overall survival? Int. J. Colorectal. Dis. 2013, 28, 1143–1149. [Google Scholar] [CrossRef] [PubMed]
- Knight, S.R.; Shaw, C.A.; Pius, R.; Drake, T.M.; Norman, L.; Ademuyiwa, A.O.; Adisa, A.O.; Aguilera, M.L.; Al-Saqqa, S.W.; Al-Slaibi, I.; et al. Global variation in postoperative mortality and complications after cancer surgery: A multicentre, prospective cohort study in 82 countries. Lancet 2021, 397, 387–397. [Google Scholar] [CrossRef]
Authors (Years) | Study Sample (Data) | Forecasting Models |
---|---|---|
Moncada-Torres et al., (2021) [4] | 36,658 non-metastatic breast cancer patients from the Netherlands Cancer Registry (NCR) dataset | Random survival forests (RF), survival support vector machines (SVM), extreme gradient boosting (XGBoost), and Cox proportional hazards (CPH) |
Kuruc et al., (2021) [5] | RNA-seq data from the Cancer Genome Atlas (TCGA) | Deep neural networks (DNN), Cox proportional hazards (CPH) |
Wang et al., (2021) [6] | 1137 patients with IB-IIA stage non-small cell lung cancer (China) and compared generalization performance on the Surveillance, Epidemiology, and End Results Program (SEER) dataset | Deep neural networks (DNN), Cox proportional hazards (CPH), SurvNet |
Bhambhvani, et al., (2021) [7] | 277 patients with genitourinary rhabdomyosarcoma from the Surveillance, Epidemiology, and End Results Program (SEER) dataset | Deep neural networks (DNN), Cox proportional hazards (CPH) |
Hou et al., (2020) [8] | 7127 breast cancer cases and 7127 matched healthy controls (China) | Extreme gradient boosting (XGBoost), random forest (RF), deep neural network (DNN), logistic regression (LR) |
Parameters | Deep Neural Networks |
---|---|
No. of hidden layers | 4 |
No. of neuron in each hidden layers | (64, 64, 128, 256) |
Activation functions in each layer | Rectified linear unit (ReLU) in hidden layers and sigmoid on output layer |
Loss function | Binary cross entropy |
Optimizer | Adaptive moments estimation (Adam) with 0.001 learning rate |
No. of Epochs | 100 |
Dropout layers for regularization | 20% dropout layer after second hidden layer and 10% after third hidden layers |
Variables | N (%) | Mean ± SD |
---|---|---|
Demographic characteristics | ||
Age, years | 52.2 ± 11.1 | |
Education, years | 10.2 ± 3.8 | |
Current residence with family member(s) | 1127 (95.7%) | |
Married | 1038 (88.1%) | |
Body mass index, kg/m2 | 24.5 ± 4.6 | |
Charlson Comorbidity Index, score | 1.0 ± 1.4 | |
Tumor size | 2.4 ± 1.8 | |
Tumor stage | ||
0 | 80 (6.8%) | |
I | 354 (30.1%) | |
II | 441 (37.4%) | |
III | 303 (25.7%) | |
Smoker | 55 (4.7%) | |
Drinker | 29 (2.5%) | |
Breast cancer history | 150 (12.7%) | |
Clinical characteristics | ||
Surgery | ||
BCS | 154 (13.1%) | |
MRM | 297 (25.2%) | |
Mastectomy with reconstruction | 727 (61.7%) | |
ASA score | 2.0 ± 0.4 | |
Chemotherapy | 788 (66.9%) | |
Radiotherapy | 675 (57.3%) | |
Hormonal therapy | 717 (60.9%) | |
Quality of care | ||
Postoperative length of stay, days | 2.9 ± 4.7 | |
Readmission in 30 days | 283 (24.0%) | |
Recurrence | 219 (18.6%) | |
Survival | 881 (74.8%) | |
Reconstruction | 125 (10.6%) | |
Preoperative quality of life | ||
Preoperative SF36 PCS score | 56.0 ± 7.6 | |
Preoperative SF36 MCS score | 48.8 ± 16.2 |
Variables | HR | p Value |
---|---|---|
Demographic characteristics | ||
Age, years | 0.98 | <0.001 |
Education, years | 0.90 | <0.001 |
Current residence with family member(s) (no vs. yes) | 0.33 | <0.001 |
Marital status (unmarried vs. married) | 0.57 | <0.001 |
Body mass index, kg/m2 | 0.96 | <0.001 |
Charlson Comorbidity Index, score | 0.81 | 0.001 |
Tumor size, cm | 0.83 | <0.001 |
Tumor stage | ||
I vs. 0 | 0.04 | 0.001 |
II vs. 0 | 0.17 | <0.001 |
≥III vs. 0 | 0.22 | <0.001 |
Smoker (no vs. yes) | 1.36 | 0.043 |
Drinker (no vs. yes) | 2.09 | 0.037 |
Breast cancer history (no vs. yes) | 2.70 | 0.001 |
Clinical characteristics | ||
Surgery type | ||
MRM vs. BCS | 0.49 | 0.001 |
Mastectomy with reconstruction vs. BCS | 0.35 | <0.001 |
ASA score | 0.35 | <0.001 |
Chemotherapy (no vs. yes) | 0.46 | <0.001 |
Radiotherapy (no vs. yes) | 0.39 | <0.001 |
Hormonal therapy (no vs. yes) | 0.29 | <0.001 |
Quality of care | ||
Postoperative length of stay, days | 0.71 | <0.001 |
Readmission in 30 days (no vs. yes) | 3.26 | <0.001 |
Recurrence (no vs. yes) | 2.17 | 0.002 |
Postoperative reconstruction (no vs. yes) | 0.39 | 0.005 |
Preoperative quality of life | ||
Preoperative SF36 PCS score | 1.02 | <0.001 |
Preoperative SF36 MCS score | 1.03 | <0.001 |
Variables | Training Dataset (n = 824) | Testing Dataset (n = 177) | p Value |
---|---|---|---|
Demographic characteristics | |||
Age, years | 52.7 ± 10.6 | 52.5 ± 13.1 | 0.148 |
Education, years | 10.1 ± 3.8 | 10.6 ± 4.0 | 0.174 |
Current residence with family member(s) | 787 (95.5%) | 168 (94.9%) | 0.900 |
Married | 722 (87.6%) | 159 (89.8%) | 0.598 |
Body mass index, kg/m2 | 24.7 ± 5.1 | 24.0 ± 3.8 | 0.481 |
Charlson Comorbidity Index, score | 1.0 ± 1.4 | 1.0 ± 1.3 | 0.570 |
Tumor size, cm | 2.4 ± 1.9 | 2.4 ± 1.4 | 0.344 |
Tumor stage | 0.690 | ||
0 | 67 (8.1%) | 7 (3.9%) | |
I | 251 (30.5%) | 57 (32.5%) | |
II | 305 (37.0%) | 67 (37.7%) | |
≥III | 201 (24.4%) | 46 (25.9%) | |
Smoker | 35 (4.2%) | 12 (6.5%) | 0.425 |
Drinker | 18 (2.2%) | 5 (2.6%) | 0.711 |
Breast cancer history | 74 (9.0%) | 18 (10.4%) | 0.755 |
Clinical characteristics | |||
Surgery type | 0.492 | ||
BCS | 118 (14.3%) | 21 (11.7%) | |
MRM | 199 (24.1%) | 55 (31.2%) | |
Mastectomy with reconstruction | 507 (61.6%) | 101 (57.1%) | |
ASA score | 2.0 ± 0.4 | 2.0 ± 0.3 | 0.676 |
Chemotherapy | 550 (66.7%) | 124 (70.1%) | 0.572 |
Radiotherapy | 473 (57.4%) | 108 (61.0%) | 0.565 |
Hormonal therapy | 496 (60.2%) | 113 (63.6%) | 0.582 |
Quality of care | |||
Postoperative length of stay, days | 2.7 ± 1.9 | 2.9 ± 1.5 | 0.711 |
Readmission in 30 days | 185 (22.4%) | 48 (27.2%) | 0.357 |
Recurrence | 138 (16.8%) | 48 (27.2%) | 0.067 |
Postoperative reconstruction Survival | 74 (9.0%) 616 (74.8%) | 18 (10.4%) 133 (75.3%) | 0.564 0.846 |
Preoperative quality of life | |||
Preoperative SF36 PCS score | 56.0 ± 7.6 | 54.1 ± 6.6 | 0.758 |
Preoperative SF36 MCS score | 48.4 ± 18.5 | 49.6 ± 4.2 | 0.863 |
Authors (Country) | No. of Subjects | Measures | Findings |
---|---|---|---|
Chiu et al., 2019 (Taiwan) [24] | 369 patients with hepatocellular carcinoma | Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and the SF-36 | 1. Overall postoperative survival was significantly associated with preoperative SF-36 physical component summary score (hazard ratio, HR = 1.05, p < 0.001) and preoperative SF-36 mental component summary score (HR = 1.03, p < 0.001). 2. Overall postoperative survival was significantly associated with preoperative FACT g total score (HR = 1.07, p < 0.001) and preoperative FACT-Hep total score (HR = 1.10, p < 0.001). |
Quinten et al., 2014 [32] | 11 different cancer sites pooled from 30 EORTC randomized controlled trials were selected for this study (7417 cancer patients) | European Organisation for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC-QLQ-C30) | Overall postoperative survival was significantly associated with preoperative EORTC-QLQ-C30 physical functioning (HR = 0.86, p = 0.0119), emotional functioning (HR = 1.13, p = 0.002), global health status (HR = 0.92, p = 0.017), and nausea and vomiting (HR = 1.17, p = 0.002). |
Heijl et al., 2010 (Netherlands) [33] | 220 patients with potentially curable esophageal adenocarcinoma | Medical Outcome Study Short Form-20 (SF-20) and Rotterdam Symptom Checklist (RSCL) | 1. Overall postoperative survival was significantly associated with preoperative SF-20 physical symptom scale (HR = 0.67, p = 0.021) and endosonographic T-stage (HR = 0.05, p = 0.003). 2. Disease-free postoperative survival was significantly associated with preoperative SF-20 physical symptom scale (HR = 0.64, p = 0.024) and endosonographic T-stage (HR = 0.03, p < 0.001). |
Chen et al., 2020 (China) [34] | 149 patients with gastric cancer | Overall postoperative survival was significantly associated with early recurrence during the study period (p = 0.011). | |
Huh et al., 2013 (South Korea) [35] | 1159 patients with colorectal cancer | Overall postoperative survival was significantly associated with early postoperative recurrence (HR = 2.42, p < 0.001) and tumor stage (HR = 2.38, p < 0.001). | |
Knight et al., 2021 [36] | 15,958 patients with colorectal and gastric cancer from 428 hospitals in 82 countries | Overall postoperative survival was significantly associated with cancer stage (odds ratio = 1.80, p = 0.036). | |
Chou et al., 2016 (Taiwan) [30] | 8425 patients over 70 years old with solid cancer | 3-month postoperative survival was significantly associated with tumor stage (II, III, IV vs. I) (HR = 1.66~4.23, p < 0.001). |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lou, S.-J.; Hou, M.-F.; Chang, H.-T.; Lee, H.-H.; Chiu, C.-C.; Yeh, S.-C.J.; Shi, H.-Y. Breast Cancer Surgery 10-Year Survival Prediction by Machine Learning: A Large Prospective Cohort Study. Biology 2022, 11, 47. https://doi.org/10.3390/biology11010047
Lou S-J, Hou M-F, Chang H-T, Lee H-H, Chiu C-C, Yeh S-CJ, Shi H-Y. Breast Cancer Surgery 10-Year Survival Prediction by Machine Learning: A Large Prospective Cohort Study. Biology. 2022; 11(1):47. https://doi.org/10.3390/biology11010047
Chicago/Turabian StyleLou, Shi-Jer, Ming-Feng Hou, Hong-Tai Chang, Hao-Hsien Lee, Chong-Chi Chiu, Shu-Chuan Jennifer Yeh, and Hon-Yi Shi. 2022. "Breast Cancer Surgery 10-Year Survival Prediction by Machine Learning: A Large Prospective Cohort Study" Biology 11, no. 1: 47. https://doi.org/10.3390/biology11010047
APA StyleLou, S. -J., Hou, M. -F., Chang, H. -T., Lee, H. -H., Chiu, C. -C., Yeh, S. -C. J., & Shi, H. -Y. (2022). Breast Cancer Surgery 10-Year Survival Prediction by Machine Learning: A Large Prospective Cohort Study. Biology, 11(1), 47. https://doi.org/10.3390/biology11010047